Education
About Us
Working with TipRanks
Follow Us
LifeMD (LFMD)
NASDAQ:LFMD
Top Page
LifeMD
(NASDAQ:LFMD)
Rating:61Neutral
Price Target:
$9.00
▼(-21.53%Downside)
Positive Factors
Revenue Guidance
Management has raised 2025 total revenue guidance to $268-275M, including Telehealth revenue of $208-213M.
Subscriber Growth
Telehealth active subscriber base grew 22% YoY to 290,660 at the end of 1Q25, indicating strong growth momentum.
Negative Factors
Regulatory Challenges
The FDA ruling that Novo Nordisk's injectable semaglutide is no longer in shortage led to a significant decline in LFMD shares.
Revenue Risks
Risks include lower than projected growth of telehealth revenue, inability to acquire and retain new patients, and higher than expected competition, which could affect the company's performance.
LifeMD (LFMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$524.47M
Dividend YieldN/A
Average Volume (3M)2.17M
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth43.07%
EPS Growth55.40%
CountryUS
Employees304
SectorHealthcare
Sector Strength40
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.01
Shares Outstanding45,447,605
10 Day Avg. Volume1,948,268
30 Day Avg. Volume2,173,610
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)-63.55
Price to Sales (P/S)0.00
P/FCF Ratio62.81
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda-9.44
Forecast
1Y Price Target
$12.00Price Target Upside4.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
LifeMD Business Overview & Revenue Model
Company DescriptionLifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
How the Company Makes MoneyLifeMD generates revenue primarily through its telehealth platform by offering subscription-based healthcare services. Patients pay for virtual consultations, which can include follow-up appointments and ongoing treatment plans, thereby creating a recurring revenue stream. Additionally, LifeMD earns money through the sale of prescription medications and personalized treatment products that are prescribed during consultations. The company may also have partnerships with healthcare providers or pharmaceutical companies, enhancing its service offerings and contributing to its revenue. Furthermore, LifeMD's business model may include ancillary services like lab testing and wellness products, broadening its revenue base.
LifeMD Earnings Call Summary
Earnings Call Date:May 06, 2025
(Q1-2025)
| % Change Since: 47.81%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call for LifeMD reflects a positive sentiment, characterized by strong revenue growth in the Telehealth segment, strategic collaborations, and expansion into new verticals. The company achieved positive GAAP net income for the first time and raised its financial guidance for the year. Despite minor challenges such as a decline in WorkSimpli subscribers and a decrease in gross margin, the company's highlights significantly outweigh the lowlights.Q1-2025 Updates
Positive Updates
Core Telehealth Revenue Growth
Core Telehealth business experienced a 70% year-over-year revenue growth, driven by the weight management program, with adjusted EBITDA reaching $5.3 million, a significant improvement from a loss of $1.3 million in the previous year.
Strategic Expansion and Collaborations
LifeMD has established strategic collaborations with LillyDirect and NovoCare to improve access to GLP-1 medications for weight management patients, enhancing its competitive position in virtual obesity care.
Positive GAAP Net Income
LifeMD reported a GAAP net income of $608,000 for the first quarter, marking the first quarter with positive GAAP net income, compared to a loss of $7.5 million in the previous year.
Growth in Subscriber Base
Telehealth subscriber base increased by 22% year-over-year to over 290,000, indicating strong customer retention and acquisition.
RexMD Brand Performance
The RexMD brand continues to perform well with growth in revenue and active patient count, especially in new verticals like hormone replacement therapy.
Expansion into New Verticals
LifeMD is entering high-growth verticals such as women’s health and behavioral health, which are expected to contribute to revenue diversification and long-term profitability.
Increased Financial Guidance
Due to the strong performance of the Telehealth business, LifeMD raised its financial guidance for 2025 with expected total revenues between $268 million to $275 million.
Negative Updates
Decline in WorkSimpli Subscribers
The number of WorkSimpli active subscribers declined by 5% to 158,000, although the segment continued to perform well financially.
Gross Margin Decline
Gross margin for the first quarter was 86.8%, a decline of 270 basis points versus the previous year, due to changes in revenue mix and temporary changes in pharmacy mix.
Company Guidance
During the recent earnings call, LifeMD provided an optimistic update on its financial guidance for 2025, fueled by the strong performance of its Telehealth business. The company raised its total revenue projection to a range between $268 million and $275 million, with Telehealth revenue expected between $208 million and $213 million. Additionally, LifeMD adjusted its consolidated adjusted EBITDA guidance to fall between $31 million and $33 million, with Telehealth adjusted EBITDA anticipated to be at least $21 million. This upward revision reflects the significant 49% increase in total revenues to $65.7 million for the first quarter, bolstered by a 70% year-over-year growth in Telehealth revenue. The company also highlighted its successful strategic initiatives, including collaborations with GLP-1 manufacturers and the expansion into women's and behavioral health.LifeMD Financial Statement Overview
Summary
LifeMD exhibits strong revenue growth but faces persistent net losses and negative equity, indicating financial instability. The high gross profit margin is a positive, yet operational inefficiencies and financial restructuring are necessary for profitability and balance sheet stability. Cash flow improvements are promising, but consistency in positive cash generation is crucial.Income Statement
The company's revenue has shown strong growth, increasing from $12.47M in 2019 to $184.97M in TTM 2024, indicating a robust upward trajectory. However, profitability remains a challenge with consistent net losses, reflected in a negative net profit margin. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. Gross profit margin is high, suggesting strong pricing power or cost management at the gross level.65
Positive
Balance Sheet
The balance sheet displays a significant negative stockholders' equity of $-5.49M in TTM 2024, raising concerns about financial stability. The debt-to-equity ratio is not meaningful due to negative equity, indicating potential leverage issues. Total assets have grown, but high liabilities overshadow the company's equity position, posing a risk. The equity ratio is negative, reflecting financial distress.50
Neutral
Cash Flow
The company has improved its operating cash flow to $17.51M in TTM 2024 from previous years, showing better cash management. Free cash flow has also improved significantly, although still modest relative to revenue. The operating cash flow to net income ratio is strong, indicating effective cash conversion despite net losses. However, historical volatility in cash flows suggests potential risks.70
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 212.45M | 152.55M | 119.03M | 92.88M | 37.29M | Gross Profit |
| 242.40M | 133.65M | 100.37M | 74.88M | 28.39M | EBIT |
| -16.14M | -14.49M | -39.69M | -54.30M | -57.82M | EBITDA |
| -6.65M | -8.21M | -39.61M | -53.95M | -57.48M | Net Income Common Stockholders |
| -18.88M | -20.60M | -45.02M | -61.32M | -60.52M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 35.00M | 33.15M | 3.96M | 41.33M | 9.18M | Total Assets |
| 72.46M | 58.48M | 25.67M | 49.92M | 13.05M | Total Debt |
| 25.10M | 18.93M | 4.13M | 1.85M | 1.06M | Net Debt |
| -9.90M | -14.21M | 168.52K | -39.48M | -8.11M | Total Liabilities |
| 76.51M | 52.91M | 32.97M | 24.10M | 13.88M | Stockholders Equity |
| -5.49T | 3.51M | -6.83M | 26.85M | 1.35M |
| Cash Flow | Free Cash Flow | |||
| 5.98M | 86.95K | -35.83M | -36.49M | -12.53M | Operating Cash Flow |
| 17.51M | 8.82M | -22.94M | -33.09M | -12.13M | Investing Cash Flow |
| -11.54M | -8.73M | -13.91M | -3.40M | -798.14K | Financing Cash Flow |
| -4.12M | 29.10M | -528.20K | 68.64M | 21.00M |
LifeMD Technical Analysis
Positive
11.47
Price Trends
7.10
Positive
6.38
Positive
5.80
Positive
Market Momentum
1.35
Negative
82.20
Negative
85.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Positive. The current price of 11.47 is above the 20-day moving average (MA) of 9.34, above the 50-day MA of 7.10, and above the 200-day MA of 5.80, indicating a bullish trend. The MACD of 1.35 indicates Negative momentum. The RSI at 82.20 is Negative, neither overbought nor oversold. The STOCH value of 85.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFMD.
LifeMD Risk Analysis
LifeMD disclosed 45 risk factors in its most recent earnings report. LifeMD reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We may use AI in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations. Q4, 2024
2.
Our use of AI systems may be subject to emerging AI laws and regulations, and our failure to comply with those laws and regulations could result in significant liability or reputational harm and, in turn, a material adverse effect on our customers, providers, and revenue. Q4, 2024
LifeMD Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $524.47M | ― | 301.60% | ― | 43.07% | 55.40% | |
57 Neutral | $225.75M | ― | 322.49% | ― | -30.66% | 36.48% | |
57 Neutral | $9.69B | ― | -56.13% | 8.92% | 5.08% | 4.43% | |
53 Neutral | $77.87M | 353.27 | 0.36% | ― | -10.82% | ― | |
53 Neutral | $5.19B | 3.33 | -45.04% | 2.83% | 17.58% | -0.66% | |
52 Neutral | $207.20M | 25.27 | -7.77% | ― | -46.95% | -237.44% | |
47 Neutral | $252.46M | ― | -30.47% | ― | ― | -22.66% |
* Healthcare Sector Average
Performance Comparison
LFMD
LifeMD
11.47
2.97
34.94%
OSUR
Orasure Technologies
2.77
-1.93
-41.06%
PETS
Petmed Express
3.78
-0.27
-6.67%
WBA
Walgreens Boots Alliance
11.19
-3.40
-23.30%
FHTX
Foghorn Therapeutics
4.30
-1.50
-25.86%
AVIR
Atea Pharmaceuticals
2.94
-0.67
-18.56%
LifeMD Corporate Events
M&A TransactionsBusiness Operations and Strategy
LifeMD Acquires Optimal Human Health MD Assets
Positive
Apr 29, 2025
On April 25, 2025, LifeMD acquired key assets from Optimal Human Health MD, a nationwide women’s health virtual care provider, marking its entry into the women’s health market. This strategic acquisition aims to address the significant unmet need for accessible, personalized, and high-quality care in women’s health, particularly in areas like menopause and osteoporosis. The acquisition aligns with LifeMD’s strategy to scale high-demand specialty care verticals, leveraging its national provider network and partnerships to deliver comprehensive virtual-first women’s health services.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.